Skip to main content

30-05-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: Dual EGFR inhibition for EGFR-mutated NSCLC

Julia Rotow outlines the rationale and preliminary findings of a study of concurrent osimertinib and gefitinib for treatment-naïve EGFR-mutated non-small-cell lung cancer (6:59).

Read transcript

Enriched treatment pathway for non-driver NSCLC

What is it and why do I need it?

Have your say on Medicine Matters

Visit the conference hub

Image Credits